Home
About Lectranal®
Research
Product supply
About us
FAQ
News
Events
LECTRANAL® MARKETS
Contact us
Preclinical toxicity study on Lectranal®
To determine the safety profile of allergy-relieving ingredient Lectranal®, a multiple-dose, 28-day toxicity study was performed on mice. The study was perfomed at the Ruđer Bošković Institute in Zagreb according to OECD protocol 407. Since Lectranal® requires an enteric delivery, in this experiment it was administered either by gastric or enteric gavage at three different dosage levels.
No mortality, adverse reactions, or behavioral changes were observed in any of the groups. There was no significant weight change in any of the animals. Feed and water consumption were unchanged compared to the controls. Urinanalysis, haematology, and biochemistry results revealed no significant difference between the treated and control groups. No changes were revealed by necropsy and there was no difference in organ weight between the treated and control animals. Histology results were normal and similar to the controls.
There were no toxicity effects of any kind as result of Lectranal® application. Taken together, these results show that Lectranal® has a good safety profile.
For the details download the report on the right.
RELATED ARTICLES
EFFICACY AND SAFETY OF LECTRANAL® IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS SYMPTOMS
How does Lectranal® work
Lectranal® and intradermal inflammatory reactions
An assay for immunoglobulines in the blood of mice treated with Lectranal®
Lectranal®, inflammatory reaction, and gene expression in mouse spleen
DOWNLOADS
pdf     225,68 KB
Preclinical toxicity study on Lectranal
Disclaimer | General Conditions Of Use | Privacy Statement | Imprint All rights reserved, Lectranal 2006

This website is intended for business to business communication only.
Distributors of the finished products are responsible for ensuring that the claims made
for and use of their products comply with the regulatory requirements of the location.
Owner of the page takes no responsibility for the misuse of the claims.
Design by: Studio2M       Powered by: CorvusCMS